Intranasal saline alone resolved symptoms in nearly 30% of children with obstructive sleep-disordered breathing (OSDB) during a 6-week run-in period.
In children with persistent symptoms after the initial run-in, no clinical or statistical difference was found between intranasal mometasone furoate and continued saline treatment.
Cumulative conservative management with saline led to a total symptom resolution rate of approximately 50% over 12 weeks.
Current evidence suggests that a 3-month trial of intranasal saline should be recommended before escalating to specialist referral or surgical intervention.
